Phase (ph) 1B/2 dose-ranging study of carfilzomib (CFZ) in combination with lenalidomide (LEN) and dexamethasone (lodex) in relapsed-refractory multiple myeloma (R/R MM)

Category Primary study
JournalHaematologica
Year 2011
This article has no abstract
Epistemonikos ID: d1e53afd55bd62b439ee4854c37cd0a28b60f004
First added on: Feb 06, 2025